TVANIO-GRF (CJC-1295 NON-DAC) 2 mg x 5 Vials – Denik Pharm

Description

Denik Pharm TVANIO-GRF (CJC-1295 NON-DAC) 2 mg is a premium research peptide formulated with Modified GRF (1-29), commonly known as CJC-1295 without DAC, a short-acting analogue of Growth Hormone Releasing Hormone (GHRH) developed for advanced endocrine and peptide research. Designed to closely mimic the activity of endogenous GHRH, this peptide provides researchers with an excellent model for investigating the body’s natural regulation of growth hormone secretion while maintaining a pharmacokinetic profile that closely resembles physiological hormone pulsatility.

Unlike the long-acting DAC-modified version, CJC-1295 NON-DAC is extensively studied for its rapid onset and shorter biological activity, making it particularly valuable in research involving growth hormone pulse dynamics, receptor responsiveness, neuroendocrine communication, and peptide pharmacology. Its physiological behavior allows scientists to examine how transient activation of the GHRH receptor influences downstream endocrine signaling under controlled laboratory conditions.

Each package contains 5 lyophilized vials, with 2 mg of CJC-1295 NON-DAC per vial, manufactured by Denik Pharm under stringent pharmaceutical-quality standards to ensure exceptional purity, stability, and reproducibility for professional scientific research.

Key Features

• Premium CJC-1295 NON-DAC (Modified GRF 1-29) research peptide
• 2 mg of high-purity peptide per vial
• 5 lyophilized vials per pack
• Short-acting analogue of Growth Hormone Releasing Hormone (GHRH)
• High-purity laboratory-grade formulation
• Designed for physiological growth hormone pulse research
• Suitable for investigations involving GHRH receptor activation, endocrine signaling, neuroendocrine physiology, and peptide pharmacology
• Manufactured under rigorous pharmaceutical-quality standards
• Intended exclusively for laboratory and scientific research applications

How It Works

CJC-1295 NON-DAC (Modified GRF 1-29) selectively binds to Growth Hormone Releasing Hormone (GHRH) receptors located within the anterior pituitary, activating intracellular signaling pathways that regulate endogenous growth hormone secretion. Because it lacks the Drug Affinity Complex (DAC) modification, researchers use this peptide to investigate natural, short-duration receptor activation and physiological hormone release patterns.

In laboratory studies, TVANIO-GRF is commonly utilized to examine GHRH receptor signaling, growth hormone pulsatility, receptor sensitivity, and downstream IGF-1 regulation. Researchers also investigate its interaction with Growth Hormone Secretagogues (GHS) such as GHRP-2, GHRP-6, and Ipamorelin to better understand the complementary mechanisms governing endocrine communication and hormone regulation.

This formulation is intended exclusively for laboratory and scientific research and is not intended for human consumption.

Contents

Active Ingredient: CJC-1295 NON-DAC (Modified GRF 1-29) – 2 mg

Packaging: 5 Lyophilized Vials